



5th International Symposium on Hepatitis Care in Substance Users • Oslo • 7 - 9 September 2016 • [www.inhsu2016.com](http://www.inhsu2016.com)

## 07/09/2016 Epidemiology and Public Health

8:00 am	<b>Registration</b> Foyer
9:00 am - 9:10 am	<b>Welcome to the Conference</b> Scandinavia Ballroom Olav Dalgard, Akershus University Hospital, Norway
9:10 am - 9:15 am	<b>Opening Statement from Community Member</b> Scandinavia Ballroom Ronny Bjørnstad, proLAR, Norway
9:15 am - 10:40 am	<b>Session A: HCV Epidemiology</b> Scandinavia Ballroom Chairperson: Magdalena Harris, London School of Hygiene and Tropical Medicine Chairperson: Tom Hemming Karlsen, University of Oslo
9:15 am - 9:35 am	<b>The Burden of HCV Infection Among PWID</b> Scandinavia Ballroom Sharon Hutchinson, Glasgow Caledonian University, United Kingdom

[Abstract](#)

### **Presentation**

9:35 am - 9:55 am	<b>The Natural History of HCV Infection</b> Scandinavia Ballroom Knut Boe Kielland, Innlandet Hospital Trust, Norway
-------------------	--

[Abstract](#)

[Presentation](#)

9:55 am - 10:10 am

**Can Health Risk Behaviours Explain the High Mortality Rate for Adults with Chronic Hepatitis C in the United States?**

Scandinavia Ballroom

Hamish Innes, Glasgow caledonian university

[Abstract](#)

[Presentation](#)

10:10 am - 10:25 am

**Effect of Combined Harm Reduction Strategies on HCV Primary and Reinfection Incidences among People Who Inject Drugs in Montreal, Canada**

Scandinavia Ballroom

Julie Bruneau, Université de Montréal

[Abstract](#)

10:25 am - 10:40 am

**The Prison Economy of Needles and Syringes: What Opportunities Exist for Hepatitis C Risk Reduction When Prices are so High?**

Scandinavia Ballroom

Andrew Lloyd, University of New South Wales, Australia

[Abstract](#)

[Presentation](#)



10:40 am - 11:00 am

**Coffee Break**

Foyer

11:00 am - 12:00 pm

**Session B: Harm Reduction**

Scandinavia Ballroom

Chairperson: Ronny Bjørnstad, proLAR, Norway

Chairperson: Matthew Hickman, University of Bristol, United Kingdom

11:00 am - 11:20 am

**State-of-the-Art Lecture: Opioid and Stimulant Substitution Treatment**

Scandinavia Ballroom

Johan Franck, Karolinska Institutet, Sweden

[Abstract](#)

[Presentation](#)

11:20 am - 11:40 am

**Sharing of Needles, Syringes and Injecting Equipment: Risk of HCV Transmission and Prevention Potential**

Scandinavia Ballroom

Holly Hagan, New York University, United States

[Abstract](#)

11:40 am - 12:00 pm

**Advances and Opportunities for Harm Reduction in Europe**

Scandinavia Ballroom

Mags Maher, EuroNPUD, United Kingdom

[Abstract](#)

[Presentation](#)

12:00 pm - 1:30 pm	<b>Lunch</b> Restaurant	
12:15 pm - 1:15 pm	<b>Industry Sponsored Symposium</b> Stockholm/Oslo	
1:45 pm - 3:00 pm	<b>Session C Oral Abstracts: Epidemiology and Public Health</b> København Chairperson: Peter Vickerman, University of Bristol, United Kingdom Chairperson: Angella Duvnjak, AIVL, Australia	<b>Session D: Oral Abstracts: Epidemiology and Public Health</b> Stockholm/Oslo Chairperson: Lisa Maher, The Kirby Institute, UNSW Australia
1:45 pm - 2:00 pm	<b>Hepatitis C and HIV Treatment Cascades among People Who Inject Drugs. Results from a Sero-Behavioural Survey among Current Injectors in Germany</b> København Ruth Zimmermann, Robert Koch Institute	<b>Molecular Epidemiology of Full-Length Hepatitis C Virus Genomes among Injecting Drug Users with Recent Infection: The Inc3 Study</b> Stockholm/Oslo Chaturaka Rodrigo, University of New South Wales

[Abstract](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

2:00 pm - 2:15 pm	<b>The Role of Incarceration in HCV Transmission amongst People who Inject Drugs: A Modelling Analysis</b> København Jack Stone, University of Bristol	<b>Liver Disease Burden and Clinical Follow-Up during a Liver Health Promotion Intervention Integrating Non-Invasive Liver Disease Screening in Drug and Alcohol Settings: The Liverlife Study</b> Stockholm/Oslo
-------------------	--	--

Jason Grebely, Kirby Institute, UNSW Australia

[Abstract](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

2:15 pm - 2:30 pm

**Stable Incidence of Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting: The HITS-P Study**

København

Evan Cunningham, UNSW Australia

**Successful Model of Testing and Linking People who Inject Drugs (PWID) to Treatment using Direct Acting Antivirals**

Stockholm/Oslo

Nalinikanta Rajkumar, Community Network for Empowerment (CoNE)

[Abstract](#)

[Abstract](#)

[Presentation](#)

2:30 pm - 2:45 pm

**Hepatitis C Virus Exposure, Infection and Associated Risk Behaviours in Two Maximum-Security Prisons in New South Wales, Australia**

København

Behzad Hajari, The Kirby Institute, UNSW Australia

**Changes in Risk Behaviours during and Following Treatment for Hepatitis C Virus Infection among People Who Inject Drugs: The ACTIVATE Study**

Stockholm/Oslo

Håvard Midgard, Akershus University Hospital

[Abstract](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

2:45 pm - 2:50 pm

**Monitoring HCV among People Who Inject Drugs in Europe: A Set of Indicators to Serve Policy and Practice**

København

Isabelle Giraudon, EMCDDA

**Exposure to opioid substitution therapy following hepatitis C notification: Implications for provision of antiviral therapies in drug treatment settings**

Stockholm/Oslo

[Abstract](#)

[Presentation](#)

2:50 pm - 2:55 pm

**Combining the Expansion of Medicated Assisted Therapies and HCV Treatment among PWID in Ukraine: Insights from Network Modeling**

København

Alexei Zelenev, Yale School of Medicine

[Abstract](#)

2:55 pm - 3:00 pm

**HCV Infection and HIV-HCV Coinfection among "New" Injectors during an HIV Outbreak in Athens, Greece: Results from the Aristotle Programme**

København

Vana Sypsa, National and Kapodestrian University of Athens

[Abstract](#)

[Presentation](#)

3:00 pm - 3:30 pm

**Coffee Break**

Sarah Larney, National Drug and Alcohol Research Centre, UNSW  
Australia

[Abstract](#)

[Presentation](#)

**Fatigue in Patients with Chronic Hepatitis C: The FAT-HEP Study. A Cross Sectional Study of Fatigue and its Relation to Substance Use and OST**

Stockholm/Oslo

Anne Øvrehus, University of Southern Denmark, Denmark

[Abstract](#)

[Presentation](#)

**Multi-Disciplinary Managed Care Networks-Lifesaving Interventions for Hepatitis C Patients**

Stockholm/Oslo

John Dillon, University of Dundee

[Abstract](#)

[Presentation](#)

Foyer

3:30 pm - 3:45 pm

**Poster Highlights**

Scandinavia Ballroom

Jason Grebely, The Kirby Institute, UNSW, Australia

3:45 pm - 5:00 pm

**Session E: Limiting the HCV Epidemic**

Scandinavia Ballroom

Chairperson: Kimberly Page, University of New Mexico Health Sciences Center, United States

Chairperson: Mary Harrod, CEO, NUAA

3:45 pm - 4:05 pm

**State-of-the-Art Lecture: HCV Treatment as Prevention**

Scandinavia Ballroom

Matthew Hickman, University of Bristol, United Kingdom

[Presentation](#)

4:05 pm - 4:25 pm

**HCV Vaccine Development: Where Do We Stand?**

Scandinavia Ballroom

Andrea Cox, John Hopkins University, United States

[Abstract](#)

[Presentation](#)

4:25 pm - 4:45 pm

**The Ebola Vaccine Experience: Cluster Randomisation and Implications for HCV Trial Design**

Scandinavia Ballroom

John-Arne Røttingen, Norwegian Institute of Public Health, Norway

## Presentation

4:45 pm - 5:00 pm      **Liver Or Die: A Peer Training Manual**  
Scandinavia Ballroom  
Saga Rönnlund, Peer-educator for Liver or Die , The Swedish Drug Users Union

## Abstract

5:00 pm - 6:30 pm      **Welcome Reception & Poster Viewing Session**  
Foyer

6:30 pm                **End of Conference Day 1**  
Scandinavia Ballroom

## **08/09/2016 Treatment and Care**

9:00 am - 10:30 am      **Session F: HCV Treatment Among PWID**  
Scandinavia Ballroom  
Chairperson: Mags Maher, EuroNPUD, United Kingdom  
Chairperson: Julie Bruneau, Université de Montréal

9:00 am - 9:20 am      **State-of-the-Art Lecture: Treatment of HCV Infection in 2016**  
Scandinavia Ballroom  
Graham Foster, University of London, United Kingdom



- 9:20 am - 9:40 am [Presentation](#)  
**HCV Treatment Trials Among PWID**  
Scandinavia Ballroom  
Gregory Dore, The Kirby Institute, UNSW, Australia
- 9:40 am - 9:55 am [Presentation](#)  
**Community Supported HCV Treatment Model in Provision of Care for PWID in Ukraine**  
Scandinavia Ballroom  
Sergii Filippovych, Treatment, Procurement and Supply management in Alliance for Public Health

[Abstract](#)

- 9:55 am - 10:10 am [Presentation](#)  
**C-EDGE CO-STAR: Risk of Reinfection Following Successful Therapy with Elbasvir (EBR) And Grazoprevir (GZR) in Persons Who Inject Drugs (PWID) Receiving Opioid Agonist Therapy (OAT)**  
Scandinavia Ballroom  
Olav Dalgard, Akershus University Hospital

[Abstract](#)

- 10:10 am - 10:25 am [Presentation](#)  
**"I got my life back!" - Patients' experiences on being cured for hepatitis C. A qualitative study of fatigue and everyday life in a group of Danish patients.**  
Oslo  
Nanette Braae Jensen, Department of Infectious Diseases, Odense University Hospital

[Abstract](#)

- 10:25 am - 11:00 am [Presentation](#)

- 10:25 am - 11:00 am **Coffee Break**

Foyer

11:00 am - 12:00 pm

**Session G: Living with HCV Infection**

Scandinavia Ballroom

Chairperson: Jude Byrne, The Australian Injecting and Illicit Drug users League

Chairperson: Phillip Bruggmann

11:00 am - 11:10 am

**Extrahepatic Manifestations of HCV Infection: Does HCV Cause Fatigue?**

Scandinavia Ballroom

Olav Dalgard, Akershus University Hospital, Norway

[Presentation](#)

11:10 am - 11:20 am

**The Patient Perspective**

Scandinavia Ballroom

Andi Hüttenmoser, Switzerland

11:20 am - 11:30 am

**"But a spoon is not equipment": Risk Behaviour and Knowledge Seeking Among HCV-infected PWID**

Scandinavia Ballroom

Aleksandra Bartoszko, Oslo and Akershus University College of Applied Social Sciences

[Abstract](#)

[Presentation](#)

11:30 am - 12:00 pm

**Panel Debate: Should HCV treatment be prioritized for people with on-going injecting drug use?**

Scandinavia Ballroom

Anne Øvrehus, University of Southern Denmark, Denmark

Martin Kåberg, Karolinska Institutet, Sweden

Sharon Hutchinson, Glasgow Caledonian University, United Kingdom

Peer Brehm Christensen, University of Southern Denmark, Denmark

Moderator: Graham Foster, University of London, United Kingdom

12:00 pm - 1:30 pm

**Lunch**

	Restaurant	
12:15 pm - 1:15 pm	<b>Industry Sponsored Symposium</b> Stockholm/Oslo	
1:45 pm - 3:00 pm	<b>Session H: Oral Abstracts: Clinical</b> København Chairperson: Georgios Zarkotos, Greek Drug Users Union, Greece Chairperson: Brian Conway, Vancouver ID Centre	<b>Session I: Oral Abstracts: Social Sciences and Community</b> Stockholm/Oslo Chairperson: Jo Neale, King's College London, United Kingdom
1:45 pm - 2:00 pm	<b>Outreach Screening and Treatment for Hepatitis C in a Drug Treatment Unit – An Exploratory Assessment of Feasibility and Cost Effectiveness</b> København Ashley Brown, Imperial College London	<b>Relationships and Injecting Dyads: Identifying Key Interpersonal Factors Underlying Injecting Behaviors and Hepatitis C Virus (Hcv) Transmission among Injecting Partnerships</b> Stockholm/Oslo Meghan Morris, University of California, San Francisco
	<a href="#">Abstract</a>	<a href="#">Abstract</a>
	<a href="#">Presentation</a>	
2:00 pm - 2:15 pm	<b>High Rates of Sustained Virological Response in People Who Inject Drugs Treated with All-Oral Direct Acting Antiviral Regimens</b> København Alain Litwin, Albert Einstein College of Medicine and Montefiore Medical Center	<b>Becoming a Buddy: Accordance and Incompatibility in the Hepatitis C Peer Support Role</b> Stockholm/Oslo Magdalena Harris, London School of Hygiene and Tropical Medicine
	<a href="#">Abstract</a>	<a href="#">Abstract</a>
	<a href="#">Presentation</a>	<a href="#">Presentation</a>
2:15 pm - 2:30 pm	<b>Real World Outcomes of Direct Acting Antiviral (DAA) Therapy for Hepatitis C (HCV) Amongst Persons Who Inject Drugs Treated in an Inner-city Hepatitis C treatment Program, Vancouver, Canada</b> København Mark Hull, BC Centre for Excellence in HIV/AIDS	<b>Qualitative Evaluation of the Decisions and Experiences of People Who Inject Drugs Who Received a Liver Disease Assessment as Part of a Liver Health Promotion Campaign: The Liverlife Study</b> Stockholm/Oslo Alison Marshall, The Kirby Institute

[Abstract](#)

[Presentation](#)

2:30 pm - 2:45 pm

**Comparison of Rates of Recurrent HCV Viremia in High-Risk Patients Receiving All-Oral and Interferon-Based Regimens**

København  
Tyler Raycraft

[Abstract](#)

[Presentation](#)

2:45 pm - 2:50 pm

**Treatment Evaluation and Uptake among Persons with Chronic Hepatitis C on Opium Substitution Therapy. Is Treatment as Prevention Realistic?**

København  
Anne Lindebo Holm Øvrehus, Odense University Hospital

[Abstract](#)

[Presentation](#)

2:50 pm - 2:55 pm

**Optimal Adherence during HCV Treatment amongst Active Drug Users at a Community Based Program in Toronto, Canada**

København

[Abstract](#)

[Presentation](#)

**Qualitative Insights into the Lived Experience of Interferon-Free Treatments**

Stockholm/Oslo  
David Whiteley, Edinburgh Napier University

[Abstract](#)

[Presentation](#)

**The Australian Response and Uptake of the New Subsidised Hepatitis C Direct Acting Anti-Virals among the Community of People Who Inject Drugs**

Stockholm/Oslo  
Jude Byrne, The Australian Injecting and Illicit Drug users League

[Abstract](#)

**Blood Borne Virus Risk Behaviours among People Who Inject Drugs in the UK: A Qualitative Exploration**

Stockholm/Oslo

Kate Mason, South Riverdale Community Health Centre

Davina Swan, King's College London

[Abstract](#)

[Abstract](#)

[Presentation](#)

2:55 pm - 3:00 pm

**Contingency Management Improves HCV Linkage and Treatment Outcomes in Persons Who Inject Drugs: A Pilot Study**

København

Brianna Norton, Montefiore Medical Center

[Abstract](#)

**Utilising Social Capital to Promote HCV Treatment in Prison**

Stockholm/Oslo

Lise Lafferty, The Kirby Institute, UNSW Australia

[Abstract](#)

[Presentation](#)

3:00 pm - 3:30 pm

**Coffee Break**

Foyer

3:30 pm - 5:00 pm

**Session J: Assessment and Management of HCV Infection**

Scandinavia Ballroom

Chairperson: Jason Grebely, The Kirby Institute, UNSW, Australia

3:30 pm - 3:50 pm

**Simplified HCV Diagnostics**

Scandinavia Ballroom

Teri Roberts, Foundation for Innovative New Diagnostics, Switzerland

[Abstracts](#)

[Presentation](#)

3:50 pm - 4:00 pm

**It's Your Liver: Peer to Peer HCV Testing and Education**

Scandinavia Ballroom

Bent Arild Stornes, ProLAR, Norway

[Abstract](#)

[Presentation](#)

4:00 pm - 4:20 pm

**Liver Disease Assessment Among PWID: The Role of Transient Elastography**

Scandinavia Ballroom

Peer Brehm Christensen, University of Southern Denmark, Denmark

[Presentation](#)

4:20 pm - 4:40 pm

**HCV Reinfection Following SVR: Clinical and Public Health Implications**

Scandinavia Ballroom

Håvard Midgard, Akershus University Hospital, Norway

[Presentation](#)

4:40 pm - 5:00 pm

**Understanding Liver Cirrhosis and its Complications**

Scandinavia Ballroom

John Willy Haukeland, Oslo University Hospital, Norway

[Abstract](#)

[Presentation](#)

- 5:00 pm **End of Conference Day 2**  
Scandinavia Ballroom
- 5:00 pm - 6:00 pm **INHSU General Assembly Members Meeting**  
Scandinavia Ballroom
- 7:00 pm - 11:00 pm **Conference Dinner**  
Posthallen

**09/09/2016 Access and Implementation**

8:30 am - 10:00 am **Session K: Parallel Workshops**  
No location

8:30 am - 10:00 am	<b>Workshop #1: Getting Involved: Peer Support</b> Skagerak Chairperson: Berne Stålenkrantz, The Swedish Drug Users Union, Sweden	<b>Workshop #2: HCV Prevention: What Works and What Doesn't?</b> København Chairperson: Holly Hagan, New York University, United States Chairperson: Eberhard Schatz	<b>Workshop #3: HCV Testing and Care in Prisons</b> Eidsvoll Chairperson: Andrew Lloyd, University of New South Wales, Australia Chairperson: Pernille Sauer	<b>Workshop #4: Liver Disease Assessment Among PWID: Hands On</b> Stockholm Chairperson: Peer Brehm Christensen, University of Southern Denmark, Denmark Chairperson: Håvard Midgard, Akershus University Hospital, Norway	<b>Workshop #5: The Low Threshold HCV Clinic</b> Bergen Chairperson: John F Dillon, University of Dundee, United Kingdom Chairperson: Leon Wylie	<b>Workshop #6: HCV Epidemiology: Populations, Data Sources and Missing Data</b> Oslo Chairperson: Matthew Hickman, University of Bristol, United Kingdom Chairperson: Gregory Dore, The Kirby Institute, UNSW, Australia Chairperson: Julie Bruneau, Université de Montréal
--------------------	---	---	---	---	---	--

[Abstract](#)

[Abstract](#)

[Abstract](#)

[Abstract](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

[Abstract](#)

[Presentation](#)

[Presentation](#)

10:00 am - 10:45 am

**Coffee Break**

Foyer

10:45 am - 12:00 pm

**Session L: Novel Models of HCV Care**

Scandinavia Ballroom

Chairperson: Gregory Dore, The Kirby Institute, UNSW, Australia

10:45 am - 11:05 am

**HCV Treatment in the Prison Setting**

Scandinavia Ballroom

Andrew Lloyd, University of New South Wales, Australia

[Abstract](#)

[Presentation](#)

11:05 am - 11:25 am

**Pharmacy Based HCV Treatment**

Scandinavia Ballroom

John F Dillon, University of Dundee, United Kingdom

[Abstract](#)

[Presentation](#)

11:25 am - 11:40 am

**Decentralised HCV Shared Care: The SACC Project**



Scandinavia Ballroom  
Lars Peters, Rigshospitalet, Denmark

[Abstract](#)

[Presentation](#)

11:40 am - 12:00 pm **New Technologies for Addressing Treatment Barriers and Treatment Adherence**  
Scandinavia Ballroom  
Jeffrey J Weiss, Mount Sinai Hospital, United States

[Abstract](#)

[Presentation](#)

12:00 pm - 1:30 pm **Lunch**  
Restaurant

12:15 pm - 1:15 pm **Industry Sponsored Symposium**  
Scandinavia Ballroom

1:45 pm - 2:45 pm **Session M: Drug Policy**  
Scandinavia Ballroom  
Chairperson: Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia  
Chairperson: Margaret Hellard, Burnet Institute, Australia

1:45 pm - 2:05 pm **War on Drugs or War on Disease?**  
Scandinavia Ballroom  
Ethan Nadelmann, Drug Policy Alliance, United States

2:05 pm - 2:25 pm **Report from United Nations General Assembly Special Session on the World Drug Problem 2016**  
Scandinavia Ballroom  
Daniel Wolfe, Open Society Foundations, United States

[Presentation](#)

2:25 pm - 2:30 pm

**HA-REACT: The European Joint Action on HIV and Coinfection Prevention and Harm Reduction - What's in it for Hepatitis?**

Scandinavia Ballroom

Jeffrey V Lazarus, Rigshospitalet, University of Copenhagen, Denmark

[Presentation](#)

2:30 pm - 2:50 pm

**Can information and communication technologies (ICTs) increase treatment opportunities for people who are homeless and people who inject drugs?**

Scandinavia Ballroom

Jo Neale, King's College London, United Kingdom

[Abstract](#)

[Presentation](#)

2:50 pm - 3:00 pm

**The INHSU Video Project**

Scandinavia Ballroom

Nikki Cavenagh, The Digital Clinic, Australia

3:00 pm - 3:15 pm

**Coffee Break**

Foyer

3:15 pm - 4:00 pm

**Session N: HCV Care in Resource-Limited Countries**

Scandinavia Ballroom

Chairperson: Janko Belin, Društvo AREAL, Slovenia

Chairperson: Jeffrey V Lazarus, Rigshospitalet, University of Copenhagen, Denmark

3:15pm - 3:35 pm

**The Georgia HCV Elimination Program**

Scandinavia Ballroom

Maia Butsashvili, Health Research Union

[Abstract](#)

[Presentation](#)

3:35 pm - 3:55 pm

**Russia: Hepatitis C Treatment Gap and Ways Forward**

Scandinavia Ballroom

Anya Sarang, Andrey Rylkov Foundation for Health and Social Justice, Russia

[Abstract](#)

3:55 pm - 4:15 pm

[Presentation](#)

**Access to DAAs From an Asian Perspective**

Scandinavia Ballroom

Giten Khwairakpam, TREAT Asia, Thailand

[Abstract](#)

[Presentation](#)

4:15 pm - 4:25 pm

**HCV Infection Among PWID: Research Priorities for Optimizing Prevention, Management and Treatment in the Era of DAAs**

Scandinavia Ballroom

Jason Grebely, The Kirby Institute, UNSW, Australia

4:25 pm - 4:30 pm

**Conference Closing**

Scandinavia Ballroom

4:30 pm

**End of Conference**

Scandinavia Ballroom